Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Merck
McKesson
Baxter
Harvard Business School

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,803,376

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,803,376 protect, and when does it expire?

Patent 6,803,376 protects FACTIVE and is included in one NDA.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 6,803,376
Title: Method of use of quinolone compounds against pneumococcal and haemophilus bacteria
Abstract:This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, particularly quinolone resistant S. pnemoniae and rare H. influenzae strains.
Inventor(s): Appelbaum; Peter C. (Hershey, PA), Credito; Kim L. (Hershey, PA), Davies; Todd (Hershey, PA), Hoellman; Diane B. (Hershey, PA), Kelly; Linda M. (Hershey, PA), Pankuch; Glenn A. (Hershey, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/569,648
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,803,376

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes   Start Trial   Start Trial Y Y USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA   Start Trial
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes   Start Trial   Start Trial Y Y USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,803,376

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 383157   Start Trial
Australia 6201600   Start Trial
Canada 2281817   Start Trial
Canada 2282066   Start Trial
Canada 2283141   Start Trial
Canada 2283352   Start Trial
Cyprus 1107381   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Mallinckrodt
Johnson and Johnson
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.